Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2023-02-02 00:00:00 ET · period of report 2023-01-31 · accession 0001209191-23-006305 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-02 | 2023-01-31 | MIRM | Vig Pamela | Head of Research, Development | A - Grant | $0.00 | +9,625 | 31.5K | +44% | $0 |
| D | 2023-02-02 | 2023-01-31 | MIRM | Vig Pamela | Head of Research, Development | A - Grant | $0.00 | +38.5K | 38.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-31 | A | A | 9,625 | $0.00 | 31,527 | D | — | — | (F1) Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan. |
| 2 | Derivative | Stock Option (right to buy) | 2023-01-31 | A | A | 38,500 | $0.00 | 38,500 | D | $23.48 · — to 2033-01-30 | 38,500 Common Stock | (F2) 1/4th of the shares vest one year after January 31, 2023 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. |